NASDAQ NMS - GLOBAL MARKET · CTMX
-0.78% · -$0.0200 · Vol 2.3M
Market closed · last close 4:00 PM ET · price as of 16:52:18 ET
CytomX Therapeutics Inc

CytomX Therapeutics Inc

Biotechnology
$2.54
Card
Relationship Map

Follow $CTMX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $CTMX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
CTMX
CytomX Therapeutics Inc
Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

36/ 100
Veridion Score
Lower range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CTMX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CTMX catalysts
About CytomX Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2015
Employees
69
Country
US

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.53
Day high
$2.65
Day low
$2.52
Previous close
$2.56
52W high
$6.75
-62.37% from high
52W low
$2.52
0% of range
Market cap
$557.8M
Beta
1.11
Shares out
217.9M
Volume
2.3M
0.61× rel vol
Avg volume
3.8M
VWAP
$2.57
Price history computed in-house
1W
-3.42%
1M
-30.41%
3M
-32.45%
1Y
-24.63%
YTD
-40.38%
SMA 50 $3.16 · below
SMA 200 $4.03 · below
52W position 0%

CTMX overview

Veridion Score
36
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CTMX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CTMX Form 4 filings
Public disclosures

Congress activity in CTMX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

CTMX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CTMX in this window.
Lobbying spend

CTMX lobbying filings, year to date.

Registered lobbying filings matched to CytomX Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CTMX in this window.
Loading news for CTMX
Analyst ratings
Sovereign unlock shows live analyst consensus for CTMX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.